anti-Cyclin D3, pAb
| Product Details | |
|---|---|
| Synonyms | CCND3; G1/S-specific Cyclin-D3 |
| Product Type | Polyclonal Antibody |
| Properties | |
| Immunogen/Antigen | Synthetic peptide. |
| Application |
Western Blot (1:2,000) |
| Crossreactivity |
Human Mouse |
| Purity Detail | Protein A purified. |
| Formulation | Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| Declaration | Manufactured by AbFrontier |
| Shipping and Handling | |
| Shipping | BLUE ICE |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 1 year after receipt when stored at -20°C. |
| Documents | |
| MSDS | No |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Cyclin D3, ~34kDa, is a member of cyclin D family that promotes cell cycle progression to the DNA systhesis (S) phase. Cyclins complexed with cyclin-dependent kinases(CDKs) mediate phosphorylation of other proteins relevant to cell proliferation. D-type cyclins and their complexing CDKs phosphorylate the retinoblastoma gene product with influences transcription of growth-controlling genes. Cyclin D3 regulates cell proliferation during hematopoiesis, carcinogenesis, and may have function in the terminally differentiated cells. In recent studies, there is reports that cyclin D3 involves in multiple myeloma and malignant precursor T cells. Essential for the control of the cell cycle at the G1/S (start) transition. Potentiates the transcriptional activity of ATF5.
1) Watson DS et al, Oncology. 1999; vol.56(1): pp.66-72. (General)
2) Weng AP, Aster JC. Cancer Cell. 2003; vol.4(6): pp.451-61. (General)
3) Hideshima T et al, Blood. 2004; vol.104(3): pp.607-18. (General)
